Chronic coronary artery disease with angina pectoris sleep disorder or anxiety state
Conditions
Interventions
Test group:Basic treatment: All patients receive treatments specified in the drug guidelines for the corresponding primary disease, including: drugs that improve prognosis (aspirin, beta blockers, sta
After enrollment, the patients were followed up at 0 days, 4 weeks and 12 weeks respectively, of which the 4th week was telephone follow-up.
Sponsors
Jiangyou Second People's Hospital
Eligibility
Sex/Gender
All
Age
18 Years to 80 Years
Inclusion criteria
Inclusion criteria: (1) According to the "2023AHA /ACC /ACCP /ASPC /NLA /PCNA Patient Management Guidelines for Chronic Coronary Artery Disease" and "2019 ESC Diagnosis and Management Guidelines for Chronic Coronary Syndrome", patients with chronic coronary artery disease, including at least one of the following: 1) Patients discharged from the hospital after all acute cardiovascular events such as acute coronary syndrome (ACS) or coronary revascularization; 2) Patients with left ventricular systolic dysfunction and known/suspected coronary heart disease (CAD) or considered ischemic cardiomyopathy; 3) Patients with stable angina symptoms (or critical symptoms such as ischemic diseases, such as dyspnea after exercise or pain in the upper limbs); 4) Patients with symptoms of angina and evidence of coronary spasm or microvascular angina; 5) Patients whose load test and coronary CTA screening are considered CCD and who have been diagnosed with chronic coronary artery disease by clinicians; 6) Patients with chronic coronary artery disease with insomnia and sleep disorders; 7) Patients with chronic coronary artery disease who are combined with anxiety. (2) Age > 18 years old, no gender limit; (3) CCS angina pectoris grade II-IV; (4) NYHA cardiac function level II-IV; (5) The subjects voluntarily participate and sign an informed consent form.
Exclusion criteria
Exclusion criteria: (1) Patients with severe liver and renal dysfunction (creatinine clearance =30ml/min or active period of nephropathy, serum aminotransferase =3 times the upper limit of clinical reference value), other severe primary diseases or mental diseases and malignant tumors that affect lifespan; (2) Hypertension that is difficult for the drug to control (systolic blood pressure =180mmHg and/or diastolic blood pressure =100mmHg); (3) Subjects with revascularization plans within 3 months; (4) Pregnant or breastfeeding women or those who have pregnancy plans within 3 years; (5) Those who have an allergic reaction or abnormal drug reaction to the test drugs and any excipients; (6) Those who have taken Bawei agarwood capsules regularly in the past month; (7) Those who have participated in other clinical drug trials within the past 3 months; (8) Patients whose expected survival period is less than 1 year; (9) According to the researcher's judgment, those who believe that it is not suitable to participate in this clinical trial.
Design outcomes
Secondary
| Measure | Time frame |
|---|---|
| Anxiety and Depression Score;A key event of adverse ischemic compound;Changes in sleep quality in Pittsburgh;Clinical deterioration of heart failure;Cardiovascular death rate;All-cause death rate;The proportion of readmissions caused by ACS;Angina pectoris grade changes; | — |
Primary
| Measure | Time frame |
|---|---|
| At the end, the proportion of individuals without angina pectoris; | — |
Countries
China
Contacts
Public ContactHongle
Jiangyou Second People's Hospital
Outcome results
None listed